A three-gene expression signature model for risk stratification of patients with neuroblastoma

Clinical Cancer Research

Volumn 18, Issue 7, 2012, Pages 2012-2023

  Garcia, Idoia ^a   Mayol, Gemma ^a   Ríos, José ^b   Domenech, Gema ^b,c   Cheung, Nai Kong V ^d   Oberthuer, André ^e   Fischer, Matthias ^e   Maris, John M ^f   Brodeur, Garrett M ^f   Hero, Barbara ^e   Rodríguez, Eva ^a   Suñol, Mariona ^a   Galvan, Patricia ^a   De Torres, Carmen ^a   Mora, Jaume ^a   Lavarino, Cinzia ^a  

^a HOSPITAL SANT JOAN DE DÉU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CHD5 GENE; CHILD; CHROMOSOME ABERRATION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG MEGADOSE; EVENT FREE SURVIVAL; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GNB1 GENE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MORPHOLOGY; NEUROBLASTOMA; NME1 GENE; ONCOGENE; OVERALL SURVIVAL; PAFAH1B1 GENE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRESCHOOL CHILD; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PTPRF GENE; RERE GENE; RISK ASSESSMENT; SCHOOL CHILD;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; CHILD, PRESCHOOL; DNA HELICASES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFANT; INFANT, NEWBORN; KAPLAN-MEIER ESTIMATE; MICROTUBULE-ASSOCIATED PROTEINS; MODELS, GENETIC; MULTIVARIATE ANALYSIS; NERVE TISSUE PROTEINS; NEUROBLASTOMA; NM23 NUCLEOSIDE DIPHOSPHATE KINASES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTORS;

EID: 84859408599     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2483     Document Type: Article

References (33)

1. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11:1466-77. (Pubitemid 23228250)
2. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007;369:2106-20. (Pubitemid 46935947)
3. Ambros PF, Ambros IM, BrodeurGM,Haber M, Khan J, Nakagawara A, et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer 2009;100:1471-82.
4. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, et al. The International Neuroblastoma Pathology Classification (the Shimada System). Cancer 1999;86:364-72. (Pubitemid 29327594)
5. Asgharzadeh S, Pique-Regi R, Sposto R, Wang H, Yang Y, Shimada H, et al. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst 2006;98:1193-203. (Pubitemid 44390990)
6. De Preter K, Vermeulen J, Brors B, Delattre O, Eggert A, Fischer M, et al. Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature. Clin Cancer Res 2010;16: 1532-41.
7. Oberthuer A, Hero B, Berthold F, Juraeva D, Faldum A, Kahlert Y, et al. Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol 2010;28:3506-15.
8. Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J, et al. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/ COG/GPOH study. Lancet Oncol 2009;10:663-71.
9. Oberthuer A, Berthold F, Warnat P, Hera B, Kahlert Y, Spitz R, et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 2006;24:5070-8. (Pubitemid 46631411)
10. Fischer M, Oberthuer A, Brors B, Kahlert Y, Skowron M, Voth H, et al. Differential expression of neuronal gene defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome. Clin Cancer Res 2006;12:5118-28. (Pubitemid 44453339)
11. Schramm A, Schulte JH, Klein-Hitpass L, Havers W, Sieverts H, Berwanger B, et al. Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene 2005;24:7902-12. (Pubitemid 41715196)
12. Wei JS, Greer BT, Westermann F, Steinberg SM, Son CG, Chen QR, et al. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res 2004;64:6883-91. (Pubitemid 39330995)
13. Ohira M, Oba S, Nakamura Y, Isogai E, Kaneko S, Nakagawa A, et al. Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell 2005;7:337-50. (Pubitemid 40544651)
14. Lavarino C, Garcia I, Mackintosh C, Cheung NK, Domenech G, Ríos J, et al. Differential expression of genes mapping to recurrently abnormal chromosomal regions characterize neuroblastic tumours with distinct ploidy status. BMC Med Genomics 2008;13:36.
15. Wang Q, Diskin S, Rappaport E, Attiyeh E, Mosse Y, Shue D, et al. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res 2006;66: 6050-62.
16. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. GenomeBiol 2002;3:Research0034.
17. Thompson PM, Gotoh T, Kok M, White PS, Brodeur GM. CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene 2003;22:1002-11. (Pubitemid 36313144)
18. Okawa ER, Gotoh T, Manne J, Igarashi J, Fujita T, Silverman KA, et al. Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas. Oncogene 2007; 27:803-10. (Pubitemid 351186313)
19. Bagchi A, Papazoglu C, Wu Y, Capurso D, Brodt M, Francis D, et al. CHD5 is a tumor suppressor at human 1p36. Cell 2007;128: 459-75. (Pubitemid 46198889)
20. Fujita T, Igarashi J, Okawa ER, Gotoh T, Manne J, Kolla V, et al. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J Natl Cancer Inst 2008;100:940-9. (Pubitemid 351957513)
21. Garcia I, Mayol G, Rodríguez E, Suñol M, Gershon TR, Ríos J, et al. Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma. Mol Cancer 2010; 9:277.
22. Lavarino C, Cheung NK, Garcia I, Domenech G, de Torres C, Alaminos M, et al. Specific gene expression profiles and chromosomal abnormalities are associated with infant disseminated neuroblastoma. BMC Cancer 2009;9:44.
23. Gambello MJ, Darling DL, Yingling J, Tanaka T, Gleeson JG, Wynshaw-Boris A. Multiple dose-dependent effects of Lis1 on cerebral cortical development. J Neurosci 2003;23:1719-29. (Pubitemid 36314727)
24. Cardoso C, Leventer RJ, Dowling JJ, Ward HL, Chung J, Petras KS, et al. Clinical and molecular basis of classical lissencephaly: mutations in the LIS1 gene (PAFAH1B1). Hum Mutat 2002;19:4-15.
25. Hailat N, Keim DR, Melhem RF, Zhu XX, Eckerskorn C, Brodeur GM, et al. High levels of p19/nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc gene amplification. J Clin Invest 1991;88:341-5.
26. Leone A, Seeger RC, Hong CM, Hu YY, Arboleda MJ, Brodeur GM, et al. Evidence for nm23 overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas. Oncogene 1993; 8:855-65. (Pubitemid 23087416)
27. Bown N, Cotterill S, Lastwska M, O'Neill S, Pearson AD, Plantza D, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999;340:1954-61. (Pubitemid 29288271)
28. Plantaz D, Mohapatra G, Matthay KK, Pellarin M, Seeger RC, Feuerstein BG. Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization.Am J Pathol 1997;150:81-9. (Pubitemid 27027099)
29. Lombardi D, Lacombe ML, Paggi MG. Nm23: unraveling its biological function in cell development. J Cell Physiol 2000;182:144-9. (Pubitemid 30022666)
30. Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004;350: 1828-37. (Pubitemid 38917249)
31. Yao M, Huang Y, Shioi K, Hattori K, Murakami T, Sano F, et al. A three-gene expression signature model to predict clinical outcome of clear cell renal carcinoma. Int J Cancer 2008;123:1126-32.
32. Hoffman AC, Danenberg KD, Taubert H, Danenberg PV, Wuerl P. A three-gene signature for outcome in soft tissue sarcoma. Clin Cancer Res 2009;15:5191-8.
33. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007;356:11-20. (Pubitemid 46041749)